CTOs on the Move


 
Kryo, Inc. is the world`s leading innovator of temperature-regulated and climate-control sleep solutions engineered to optimize health and wellness through enhanced quality sleep and patented technology. Kryo ranks no. 615 on the 2020 Inc. 5000 list.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.kryoinc.com
  • 144 Talbert Pointe Dr
    Mooresville, NC USA 28117
  • Phone: 704.235.6831

Executives

Name Title Contact Details

Funding

Kryo raised $20M on 12/23/2020

Similar Companies

American Clinical Research Services

American Clinical Research Services is a company that provides clinical research services.

HPS Group

HPS Group is a Silver Spring, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

East Tennessee Behavioral Health

East Tennessee Behavioral Health is a hospital and treatment facility for adolescents and adults struggling with mental health concerns such as anxiety disorders, depression, bipolar disorder, and posttraumatic stress disorder (PTSD).

Neurotrope Inc

Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage.  Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions.  These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization.  In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.